Piper Sandler assumed coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $76 price target The firm cites the potential of ALXN1840, a treatment for Wilson disease, for the Overweight rating. Monopar plans to file approval for ALXN1840 by early 2026 and Piper sees “strong odds of FDA approval, citing the Phase 3 data and the unmet need in Wilson disease specifically in patients with neurologic symptoms. It believes ALXN1840 has “significant value creating potential” for shareholders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue